“ Dexmedetomidine inhibits inflammation and angiogenesis and alleviates esophageal cancer progression through ITGA6/PI3K/AKT pathway: Dexmedetomidine inhibits esophageal cancer progression” (2026) Indian Journal of Experimental Biology (IJEB), 64(01), pp. 15–32. doi:10.56042/ijeb.v64i01.22881.